NeuroThera Labs Inc. (TSXV: NTLX), a clinical-stage pharmaceutical company and subsidiary of SciSparc Ltd., has completed manufacturing of its investigational product SCI-110 and secured the required batch release certification from a European Qualified Person (QP). This regulatory milestone authorizes shipment of clinical trial material to participating study sites and supports the initiation of patient enrollment in the company's FDA-approved Phase IIb clinical trial for Tourette Syndrome (TS) in adults. The announcement, reported via NEWMEDIAWIRE, signals that NeuroThera is moving from preparatory activities into the operational phase of its trial.
The QP batch release is significant because it confirms that the manufactured drug meets the necessary quality standards for use in human clinical trials. Without this certification, the company could not legally ship the investigational product to study sites, and patient enrollment would be delayed. The release also enables site activation activities, which have already been completed at all three participating clinical centers: Yale Child Study Center at Yale School of Medicine in New Haven, Connecticut, USA; Hannover Medical School in Hanover, Germany; and Tel Aviv Sourasky Medical Center in Tel Aviv, Israel. All sites are now prepared to receive clinical trial drug supplies following the QP release, and the company expects investigational product shipments to study sites in the near term.
Completion of site initiation activities across all participating centers, combined with the successful European QP release, marks a significant operational milestone for NeuroThera. It positions the company to advance toward patient enrollment in its Phase IIb trial for TS. The study is evaluating SCI-110's efficacy, safety, and tolerability in adults with TS, a condition with substantial unmet treatment needs. SCI-110 is NeuroThera's proprietary, patent-protected cannabinoid-based drug candidate that combines dronabinol and palmitoylethanolamide (PEA) in a single oral dosage form.
The implications of this announcement extend beyond logistics. For a clinical-stage company, the ability to manufacture and release clinical trial material is a critical gating factor. Demonstrating control over this process reduces the risk of delays and provides confidence that the trial can proceed as planned. The involvement of three internationally recognized clinical sites—Yale, Hannover Medical School, and Tel Aviv Sourasky—also lends credibility to the study and may facilitate broader acceptance of the results. For patients with Tourette Syndrome, who often face limited treatment options, the progress of a novel drug candidate like SCI-110 represents a potential new therapeutic avenue. The company's forward-looking statements note that the initiation of patient enrollment and the expected timing for investigational product shipments are subject to risks and uncertainties, which are described in its continuous disclosure documents filed on SEDAR+ (www.sedarplus.ca).
As NeuroThera moves toward patient enrollment, the successful QP release and site initiations are tangible steps that could bring SCI-110 closer to becoming a treatment option for Tourette Syndrome. The company's ability to execute on these operational milestones will be closely watched by investors and the medical community alike.
